The therapeutic effect and mechanism of brigatinib tablets

Brigatinib tablets, as an oral targeted therapy drug for non-small cell lung cancer (NSCLC), have demonstrated significant clinical therapeutic effects in recent years. It is mainly targeted at ALKpositive NSCLC patients, and effectively inhibits the growth and spread of tumors through a specific mechanism of action.

According to clinical trial data, up to 83% of patients treated with brigatinib experienced tumor shrinkage. This number intuitively reflects the strong anti-tumor activity of brigatinib. Some patients even achieve complete remission, which means the tumor is effectively controlled in a short period of time.

In addition to its direct inhibitory effect on tumors, brigatinib can also significantly prolong patient survival. This is undoubtedly an important therapeutic target for ALKpositive NSCLC patients. Brigatinib provides patients with more survival time and treatment opportunities by continuously and stably controlling the disease.

Brigatinib has also shown certain effects in preventing lung cancer recurrence and metastasis. This is particularly important for patients taking early brigatinib. By reducing the risk of recurrence and metastasis, brigatinib helps improve patients' long-term survival and quality of life.

Brigatinib can specifically bind to ALK fusion protein, thereby inhibiting its kinase activity. This combination is highly selective, ensuring that the drug mainly acts on tumor cells and has less impact on normal cells. By inhibiting the activity of ALK kinase, brigatinib further blocks the signaling pathway in tumor cells. This causes tumor cells to lose key signals required for growth and proliferation, and then fall into a state of stasis or be induced to undergo apoptosis.

References:

https://www.cancer.gov/publications/dictionaries/cancer-drug/def/brigatinib

https://www.alunbrig.com/hcp/efficacy/efficacy-post-crizotinib